Skip to content

Study on key technologies and artificial intelligence prediction model for prevention and treatment of acute large-vessel occlusion stroke in the western Sichuan Plateau region

Study on key technologies and artificial intelligence prediction model for prevention and treatment of acute large-vessel occlusion stroke in the western Sichuan Plateau region

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092762
Enrollment
Unknown
Registered
2024-11-22
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Endovascular Treatment Group for Large Vessel Occlusion Stroke in the Western Sichuan Plateau Region:NA
Western Sichuan Plateau Region Large Vessel Occlusion Stroke Without Endovascular Treatment Group:NA

Sponsors

Ya'an People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 years and above; (2) Frequently residing in high-altitude areas of western Sichuan (the altitude of the permanent residence area is higher than 1500 meters); (3) Clinical diagnosis of AIS and the presence of large vessel occlusion confirmed by CTA/DSA; (4) The time interval between the last normal time and the group was within 24 hours; (5) Signed informed consent and able to cooperate with the examination and complete the study.

Exclusion criteria

Exclusion criteria: (1) Pre-onset mRS score >2; (2) Combined intracranial hemorrhage or preexisting large cerebral infarction manifestation confirmed by CT/MRI; (3) Clinical history, previous imaging or clinical judgment suggestive of craniocerebral tumor, arteriovenous malformation, or intracranial artery entrapment; (4) History of head trauma in the previous 3 months; (5) Suffering from severe cardiovascular disease, respiratory disease, endocrine disease and other chronic diseases, malignant tumors or life expectancy less than 6 months; (6) Platelets 3.0. (7) Pregnant or lactating women; (8) Suffering from severe mental illness or cognitive impairment that prevents them from cooperating with the study; (9) Already participating in other clinical studies; (10) Other conditions deemed by the investigator to be unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with neurologic recovery to functional independence at 90 days after disease onset;

Secondary

MeasureTime frame
Functional ending;death;Revascularization rate;Neurological function improvement rate;Quality of life assessment;Cognitive function assessment;Infarct volume within 5-7 days(Imaging indicators);

Countries

China

Contacts

Public ContactWang Jian

Ya'an People's Hospital

wangjian0724@126.com+86 135 5006 4528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026